Protective Effects of a Novel Agonist of Galanin Receptors Against Doxorubicin-Induced Cardiotoxicity in Rats
- 95 Downloads
The clinical use of antineoplastic agent doxorubicin (DOX) is limited due to its cardiotoxic action. [βAla14, His15]-galanine (2–15) (G) is a novel synthetic agonist of galanin receptors GalR1-3 having cardioprotective properties in animal models in vivo. The aim of the present study was to explore effects of G on DOX-induced cardiotoxicity. Wistar rats were divided into four groups and treated with DOX (D group), DOX and G (D + G group), G (G group), and saline (control). Before treatment and at the end of the study, concentration of thiobarbituric acid reactive substances (TBARS) and activity of creatine kinase-MB (CK-MB) were determined in blood plasma, the animals were weighed, and cardiac function was evaluated by echocardiography. At the end of experiments, the hearts were used to determine energy metabolites and mitochondrial respiration in permeabilized fibers. After an 8-week study, D group exhibited a pronounced cardiac failure, the absence of weight gain, an increased plasma TBARS concentration, and CK-MB activity. These disorders were accompanied by a reduced myocardial content of high-energy phosphates and mitochondrial respiratory parameters. Co-administration of G with DOX significantly decreased plasma TBARS level and prevented an increase in plasma CK-MB activity. In D + G group, myocardial contents of ATP, PCr, total adenine nucleotides, and total creatine as well as myocardial PCr/ATP ratio and the respiratory control index were higher than in D group at the end of the experiments. Peptide G significantly improved parameters of left ventricular (LV) function and caused weight gain in animals of D + G group. These results suggest that peptide G may be a potential pharmacological agent that attenuates the cardiotoxic effects of DOX.
KeywordsDoxorubicin Cardiotoxicity Galanin receptor agonist Rats Cardiac function TBARS Myocardial bioenergetics
The authors are grateful to Dr. A. Prosvirnin for carrying out echocardiography studies and processing the results. This study was supported by the Russian Foundation for Basic Research (Grant No. 18-015-00008).
Compliance with Ethical Standards
Conflict of interest
The authors declare that they have no conflict of interest.
All applicable international and national guidelines for the care and use of animals were followed. The experiments with animals were approved by the Bioethical Committee for Animal Care of National Medical Research Center for Cardiology (Permission No. 12 of 19 September 2017).
Informed consent was obtained from all individual participants included in the study.
- 2.Wojtacki, J., Lewicka-Nowak, E., & Lesniewski-Kmak, K. (2000). Anthracycline-induced cardiotoxicity: Clinical course, risk factors, pathogenesis, detection and prevention—review of the literature. Medical Science Monitor, 6(2), 411–420.Google Scholar
- 4.Hayward, R., & Hydock, D. S. (2007). Doxorubicin cardiotoxicity in the rat: An in vivo characterization. Journal of the American Association for Laboratory Animal Science, 46(4), 20–32.Google Scholar
- 6.Cusack, B. J., Gambliel, H., Musser, B., Hadjokas, N., Shadle, S. E., Charlier, H., & Olson, R. D. (2006). Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism. Cancer Chemotherapy and Pharmacology, 58(4), 517–526. https://doi.org/10.1007/s00280-006-0199-4.CrossRefGoogle Scholar
- 8.Swenson, C. E., Bolcsak, L. E., Batist, G., Guthrie, T. H. Jr., Tkaczuk, K. H., Boxenbaum, H., et al. (2003). Pharmacokinetics of doxorubicin administered i.v. as Myocet (TLC D-99; liposome-encapsulated doxorubicin citrate) compared with conventional doxorubicin when given in combination with cyclophosphamide in patients with metastatic breast cancer. Anti-Cancer Drugs, 14(3), 239–246. https://doi.org/10.1097/01.cad.0000060626.61556.da.CrossRefGoogle Scholar
- 10.Faber, M., Coudray, C., Hida, H., Mousseau, M., & Favier, A. (1995). Lipid peroxidation products, and vitamin and trace element status in patients with cancer before and after chemotherapy, including adriamycin. A preliminary study. Biological Trace Element Research, 47(1–3), 117–123. https://doi.org/10.1007/BF02790108.CrossRefGoogle Scholar
- 14.Octavia, Y., Tocchetti, C. G., Gabrielson, K. L., Janssens, S., Crijns, H. J., & Moens, A. L. (2012). Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies. Journal of Molecular and Cellular Cardiology, 52(6), 1213–1225. https://doi.org/10.1016/j.yjmcc.2012.03.006.CrossRefGoogle Scholar
- 15.Tokarska-Schlattner, M., Zaugg, M., da Silva, R., Lucchinetti, E., Schaub, M. C., Wallimann, T., & Schlattner, U. (2005). Acute toxicity of doxorubicin on isolated perfused heart: Response of kinases regulating energy supply. American Journal of Physiology Heart and Circulatory Physiology, 289(1), H37–H47. https://doi.org/10.1152/ajpheart.01057.2004.CrossRefGoogle Scholar
- 16.Nicolay, K., Aue, W. P., Seelig, J., van Echteld, C. J., Ruigrok, T. J., & de Kruijff, B. (1987). Effects of the anti-cancer drug adriamycin on the energy metabolism of rat heart as measured by in vivo 31P-NMR and implications for adriamycin-induced cardiotoxicity. Biochimica et Biophysica Acta, 929(1), 5–13.CrossRefGoogle Scholar
- 18.Ueno, M., Kakinuma, Y., Yuhki, K., Murakoshi, N., Iemitsu, M., Miyauchi, T., & Yamaguchi, I. (2006). Doxorubicin induces apoptosis by activation of caspase-3 in cultured cardiomyocytes in vitro and rat cardiac ventricles in vivo. Journal of Pharmacological Sciences, 101(2), 151–158. https://doi.org/10.1254/jphs.FP0050980.CrossRefGoogle Scholar
- 23.Pisarenko, O., Timotin, A., Sidorova, M., Studneva, I., Shulzhenko, V., Palkeeva, M., et al. (2017). Cardioprotective properties of N-terminal galanin fragment (2–15) in experimental ischemia/reperfusion injury. Oncotarget, 8(60), 101659–101671. https://doi.org/10.18632/oncotarget.21503.CrossRefGoogle Scholar
- 27.Turner, P. V., Brabb, T., Pekow, C., & Vasbinder, M. A. (2011). Administration of substances to laboratory animals: Routes of administration and factors to consider. Journal of the American Association for Laboratory Animal Science, 50(5), 600–613.Google Scholar
- 28.Bergmeyer, H. U. (1974). Methods of enzymatic analysis (pp. 1464–1467 1772–1776, 1777–17781, 2127–2131). New York: Academic Press.Google Scholar
- 30.Curtis, M. J., Bond, R. A., Spina, D., Ahluwalia, A., Alexander, S. P., Giembycz, M. A., et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. British Journal of Pharmacology, 172(14), 3461–3471. https://doi.org/10.1111/bph.12856.CrossRefGoogle Scholar
- 31.Tabaczar, S., Koceva-Chyla, A., Czepas, J., Pieniazek, A., Piasecka-Zelga, J., & Gwozdzinski, K. (2012). Nitroxide pirolin reduces oxidative stress generated by doxorubicin and docetaxel in blood plasma of rats bearing mammary tumor. Journal of physiology and pharmacology, 63(2), 153–163.Google Scholar
- 32.Alimoradi, H., Barzegar-Fallah, A., Hassanzadeh, G., Mohammadi-Rick, S., Asadi, F., Delfan, B., et al. (2012). The cardioprotective effects of an antiemetic drug, tropisetron, on cardiomyopathy related to doxorubicin. Cardiovascular Toxicology, 12(4), 318–325. https://doi.org/10.1007/s12012-012-9175-x.CrossRefGoogle Scholar
- 35.Kakuyama, H., Kuwahara, A., Mochizuki, T., Hoshino, M., & Yanaihara, N. (1997). Role of N-terminal active sites of galanin in neurally evoked circular muscle contractions in the guinea-pig ileum. European Journal of Pharmacology, 329(1), 85–91. https://doi.org/10.1016/S0014-2999(97)10109-1.CrossRefGoogle Scholar
- 37.Liu, H. X., Brumovsky, P., Schmidt, R., Brown, W., Payza, K., Hodzic, L., et al. (2001). Receptor subtype-specific pronociceptive and analgesic actions of galanin in the spinal cord: Selective actions via GalR1 and GalR2 receptors. Proceedings of the National Academy of Sciences of the USA, 98(17), 9960–9964. https://doi.org/10.1073/pnas.161293598.CrossRefGoogle Scholar
- 38.Lundstrom, L., Sollenberg, U. E., Bartfai, T., & Langel, U. (2007). Molecular characterization of the ligand binding site of the human galanin receptor type 2, identifying subtype selective interactions. Journal of Neurochemistry, 103(5), 1774–1784. https://doi.org/10.1111/j.1471-4159.2007.04959.x.CrossRefGoogle Scholar
- 41.Torres, V. M., & Simic, V. D. (2012). Doxorubicin-induced oxidative injury of cardiomyocytes—do we have right strategies for prevention? In M. Fiuzapp (Ed.), Cardiotoxicity of oncologic treatments (pp. 89–130). Rijeka: InTech Europe.Google Scholar
- 42.Lebrecht, D., Geist, A., Ketelsen, U.-P., Haberstroh, J., Setzer, B., & Walker, U. A. (2007). Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. British Journal of Pharmacology, 151(6), 771–778. https://doi.org/10.1038/sj.bjp.0707294.CrossRefGoogle Scholar
- 43.QuanJun, Y., GenJin, Y., LiLi, W., YongLong, H., Yan, H., Jie, L., JinLu, H., Jin, L., Run, G., & Cheng, G. (2017). Protective effects of dexrazoxane against doxorubicin-induced cardiotoxicity: A Metabolomic study. PLoS ONE, 12(1), e0169567. https://doi.org/10.1371/journal.pone.0169567.CrossRefGoogle Scholar
- 44.Héon, S., Bernier, M., Servant, N., Dostanic, S., Wang, C., Kirby, G. M., et al. (2003). Dexrazoxane does not protect against doxorubicin-induced damage in young rats. American Journal of Physiology Heart and Circulatory Physiology, 285(2), H499–H506. https://doi.org/10.1152/ajpheart.00047.2003.CrossRefGoogle Scholar